Control Measures Taking Place In The Process Of Drug Discovery Is Majorly Triggering Growth of Mycoplasma Testing Market

The global mycoplasma testing market is expected to reach a value of USD 1.4 billion by 2025, according to a new report by Grand View Research, Inc. With growing R&D investments in the field of life sciences, the demand for mycoplasma testing products are anticipated to rise in the near future. Huge opportunities in the life sciences segment are spurring the market growth. Hence, a large amount of investment is being made in the biotechnology and pharmaceutical industries with rising level of healthcare spending across the globe. This is expected to trigger high growth of mycoplasma testing market.

Investment in R&D activities by pharmaceutical and biotechnology companies is increasingly being supported by the government. Researches involving drug discovery and development, receive funding from the governmental bodies to a great extent. Moreover, governmental initiatives in the form of awareness campaigns for chronic diseases such as cancer are also encouraging research-based activities. Thus, the aforementioned factors are expected to drive the market growth.

Mycoplasma contamination of cell culture is a growing concern for most of the research scientists for decades. Mycoplasma infection arises majorly from laboratory workers as human mycoplasma contamination occurs at a faster rate. In order to combat further contamination, mycoplasma tests are being conducted, which is expected to increase the demand of the related products.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• In 2016, kits & reagents dominated the market and is also expected to show highest CAGR over the forecast period owing to its wider application in mycoplasma tests
• Amongst the technology segment, Polymerase Chain Reaction (PCR) held the largest share in 2016 owing to the delivery of fast & accurate results associated with this technology
• Cell line testing is anticipated to exhibit highest CAGR over the forecast period due to the increasing risk of cell line contamination
• In 2016, pharmaceutical and biotechnology companies accounted for the largest market share due to rising number of research activities in drug discovery and development
• North America dominated the market in 2016 owing to rising healthcare spending levels and government funding for life science-related research
• Some of the key players are Merck KGaA; Sigma-Aldrich Co.; Thermo Fisher Scientific; Lonza Group Ltd.; Charles River Laboratories International, Inc.; PromoCell GmbH; and Bionique Testing Laboratories, Inc.

Click Here For Access Full Report: https://goo.gl/9Uv7PK

Promote Awareness Pertaining To Efficient Prevention Measures Globally, Which Is Expected To Contribute Of Infection Control Market Growth

The global infection control market is expected to reach USD 258.3 billion by 2025, according to a new report by Grand View Research, Inc. The market is driven by rising concerns with respect to a significant upsurge in hospital acquired infections globally. This is believed to facilitate greater penetration of infection control products. An influx in development of new biologics and subsequent demand for sterilized formulations serve as key growth factors for the overall infection control market. The healthcare organizations are focused on implementing strategies for early recognition, reporting, isolation, and surveillance of disease episodes of potential public health concern. In addition, increasing number intensive training modules, for nurses and other medical staff, on infection prevention and control is presumed to provide high potential for extensive usage of infection control products over the coming years.

For instance, College of Nurses of Ontario released guidelines concerning standard practices, that is focused on maintaining hand hygiene to reduce contamination and spread of infection. Furthermore, Centers for Disease Control and Prevention (CDC) has released guidelines for disinfection and sterilization for efficient usage of infection control products by healthcare personnel in wide array of healthcare settings such as ambulatory care, home care, hospitals, and others. As a consequence of the aforementioned factors, it is presumed that there will be significant improvement in the overall penetration rate of infection prevention and control products, which is also anticipated to fuel the market demand as well as the revenue to unprecedented heights.

View summary of this report, Click Here 

Further key findings from the report suggest:

• In the type segment, services are predicted to observe exponential growth as a consequence of increasing presence of third-party reprocessors and outsourcing of sterilization as a result of associated cost efficiency
• In the end-use segment, hospitals accounted for substantial share in 2016, as a consequence of high clinical urgency to curb the growing incidence of hospital acquired infections
• North America captured a dominant share of the overall infection control market owing to extensive infection prevention activities being implemented in hospitals, medical device and pharmaceutical companies
• The market in Asia Pacific is projected to witness exponential growth during the forecast period as a result of increasing awareness pertaining to spread of infections within healthcare settings and measures for prevention
• The competitive environment is marked by companies adopting sustainability strategies such as geographical expansion and mergers & acquisitions resulting in significant growth in their market share
• For instance, in July 2016, the Getinge Group acquired 1stCall Mobility Ltd, a company specializing in supplying rental equipment. This acquisition was carried out as a part of the company’s expansion strategy

Click Here For Access Full Report : https://goo.gl/Bf9psm

Weight Management Made Easier with Smart Wearables!

Fast and easy foods to match our fast and hectic requirements have given rise to weight gain and obesity. Excess weight has got with it health problems such as diabetes, hypertension, orthopedic, and other health problems. This has given rise to an awareness regarding weight loss and management.  

The New Gizmo in Town

LVL Kickstart is the first wearable to monitor body hydration in real time. This little smart wearable keeps a tab on the heart rate, hydration level, and activity to optimize the workout regime. It provides the wearer with real-time alerts of how much fluid they require and the best performance boost they require.

LVL use infrared light to measure the water content in the blood altering the wearer of how much and when to drink water. It also tracks activities using distance, step, and calorie tracker. The wearable provides continuous heart rate (HR) monitoring and training. 

Exercises and food & nutrition are integral parts of weight management. For effective weight loss, the body also requires adequate rest and sleep to allow the body to recuperate. LVL comes with added feature to track advanced REM (Rapid Eye Movement), automatic sleep tracking with a smart alarm, and deep sleep metrics. LVL goes a step further and provides mood inputs allow the gadget to predict how well the user will sleep, perform their activities, and how it will in turn affect their future moods. 

The gadget is BLE (Bluetooth) enabled and can communicate with phones, tablets, watches, and other devices. The LVL comes with a free mobile app that is compatible with both iOS as well as Android devices. The fitness wearable also allows the wearer to see historical trends and patterns using their mobile app. The device comes with an internal memory to store integral information when the phone is not nearby.  

Market Insights

The weight management market is expected to reach USD 442.3 billion by 2025; according to a new report by Grand View Research, Inc. Urbanization, unhealthy eating and lifestyle habits coupled with hectic and sedentary lifestyle has given rise to weight gain and obesity.

Competitive Insights

Ethicon Endo-surgery, Inc.; Ethicon US, LLC: Herbalife International, Inc.; and GOLD’S GYM are some of the key participants of the weight management market. Globally, these companies hold strong positions, which are mainly due to the lack of availability of their products and services commercially. 

Read More: http://www.grandviewresearch.com/industry-analysis/weight-management-market

North America OTC hyaluronic acid (HA) market is expected to reach a value of USD 41.3 billion by 2024

The increasing number of obese people owing to the lack of physical activity and higher consumption of fast food & alcohol, especially by the younger population are some of the factors accounting for growth.

View summary of this report, Click Here 

Orthopedic applications of HA are expected to emerge as the most lucrative segment of this market. This can be attributed to the growing target audience above 60 years, suffering from various joint disorders such as rheumatoid arthritis and osteoarthritis coupled with the introduction of new products catering to this population subset. In addition, increase in the number of arthritis-related hospitalization cases and growing awareness amongst the healthcare professionals regarding excellent physiochemical properties of hyaluronic acid is expected to drive the demand. However, the dermatology segment in the U.S. was the largest segment in 2015 accounting for almost 95.2% of the total U.S. OTC hyaluronic acid market. The growing population of women between 20 and 65 years of age and increasing awareness regarding the benefits of HA are some of the crucial factors driving the surging demand for hyaluronic acid in dermatological procedures.

Hyaluronic acid (HA) stimulates the synthesis of a protein that plays a crucial role in supporting skin structure and collagen, which declines with age leading to wrinkle formation. The growing demand for HA as a topical skin cream or serum coupled with the increasing presence of market participants in this sector is indicative of future growth. The rising awareness regarding the benefits of HA in skin care products for penetrating the dermis more effectively as compared to collagen is also anticipated to propel the market trend. According to various reports, approximately 27% of the total U.S. women population belong to the age group of 45 to 65 years, which is one of the crucial factors responsible for the surging demand for anti-wrinkle creams.

Some of the key players are Shiseido Co., Ltd.; Lindberg Nutrition & GeniusCentral Systems; Nature’s Way Products, LLC; NOW Foods; NeoCell Corporation; Source Naturals, Inc.; Doctors Best; derma e; and Earth Science Naturals

Click Here For Access Full Report : https://goo.gl/zog9y3

Revenue Cycle Management (rcm) Market Is Expected To Reach USD 65.2 Billion By 2025

The healthcare system is witnessing a paradigm shift primarily due to the changing dynamics of the business models.

These changing dynamics of the hospital industry in developed regions is expected to involve centralization and digitalization of the back-end processes, thereby demanding the implementation of revenue cycle management, which is anticipated to positively affect the market growth.

The healthcare industry is extremely vast and its centralization will help in synchronizing the entire work process along with providing economic benefits. Almost all industries aim to achieve lean management and six-sigma incorporation in their work culture to optimize resource usage and increase efficiency.

Furthermore, development of value-added services, i.e., integration of RCM system with other healthcare IT solutions such as practice management, Electronic Health Record (EHR), Computerized Physician Order Entry (CPOE) is anticipated to propel demand over the forecast period. For instance, Kareo, Inc. are multiple software enlisted in their portfolio that find high application in integrated solutions along with being used as standalone options.

View summary of this report, Click Here 

Further Key Findings From The Study Suggest:

• Services are expected to witness highest growth at a CAGR of over 11.0%. In particular, denial management and accounts receivable services are expected to be highly outsourced over the forecast period.
• Integrated solutions are anticipated to be the fastest growing segment. These can be used cohesively along with various other software to enhance efficiency and communication across different departments.
• The web-based segment is predicted to dominate the RCM market in 2025. These services are more affordable than cloud-based solutions.
• Hospitals and other end-users are expected to be the most lucrative segments over the next 8 years. To further support the segment, physician offices are also expected to contribute stable revenue, thereby promoting overall market growth.
• Asia Pacific followed by Latin America are expected to report fastest CAGR for the next 9 years. Furthermore, regions in MEA such as Saudi Arabia, Egypt, and Abu Dhabi, which are currently undergoing IT infrastructure development are expected to present lucrative opportunities.
• Major participants include McKesson Corporation; Epic Systems; Cerner Corporation; CareCloud Corporation; Kareo, Inc.; The SSI Group, LLC; Quest Diagnostics, Inc.; eClinicalWorks; athenahealth, Inc.; and Allscripts. Other firms include AdvantEdge Healthcare Solutions, Anthelio Healthcare Solutions, Greenway Health, LLC; and NextGen Healthcare

Click Here For Access Full Report : https://goo.gl/mLW2ry

Immunohistochemistry (IHC) market is estimated to reach a value of USD 3.1 billion by 2025

The global immunohistochemistry (IHC) market is estimated to reach a value of USD 3.1 billion by 2025, according to a new report by Grand View Research, Inc. The rising prevalence of cancer and increasing healthcare expenses driven by expanding aging population base are recognized to be the most influential factors driving the growth of the immunohistochemistry market. Furthermore, the rapid growth of biotech industry highlighted by increase in growth and revenue coupled with increase in stock market capitalization will nurture the growth.

Cancer has high morbidity and mortality risk associated with them. The diagnosis of the disease is majorly dependent on the stage of the disease at admission. This has led to the high demand of immunohistochemistry products. IHC staining process is performed on cancer tissues to reveal the presence of HER2 receptors and/or hormone receptors on their surface. This information plays a vital role in planning the treatment for the disease, creating a demand for immunohistochemistry products. In addition, the rising popularity of targeted immunotherapy and biologic therapy for anticancer drug development and the increasing approvals of the same by the FDA to treat specific types of cancer are expected to benefit the growth in the long run.

Other important factors driving growth include the alarming rise in healthcare spending and the shift in focus on value-based healthcare solutions. In 2015, the U.S. healthcare spending witnessed an increase of 5.8% to reach a value of USD 3.2 trillion. To curb the issue and establish a more value-based healthcare delivery, hospitals and care facilities are adopting a more specific and targeted therapy for better outcomes.

View summary of this report, Click Here 

Further key findings from the study suggest:

• North America registered the largest growth rate in the immunohistochemistry market in 2016
• The APAC region is expected to witness the fastest growth owing to increasing healthcare expenses driven by expanding aging population offering significant growth opportunities for players
• The hospitals and diagnostic laboratories segment accounted for the largest share of the immunohistochemistry market, by end-use due to the growing application of immunohistochemistry products for diagnostic procedures
• The antibody segment accounted for the largest share of immunohistochemistry market due to the increase in approvals by regulatory bodies for therapeutic antibody products
• Key players mapped in the report include Abcam plc, Agilent Technologies, BioSB, Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Merck Millipore, PerkinElmer Inc., and Thermo Fisher Scientific Inc.

Click Here For Access Full Report : https://goo.gl/ewktF3

Electronic Data Capture (EDC) Systems Market Growth Is Expected To Reach USD 1.16 Billion By 2025

The rising demand for software solutions in clinical trials, increasing R&D expenditure by companies in healthcare, supportive government initiatives to boost trials, and increasing number of potential customers implementing Electronic Data Capture (EDC) systems are some of the key factors contributing to the market growth.

The market is growing rapidly owing to the technological advancements in eClinical solutions and this is anticipated to serve this industry with future growth opportunities. Furthermore, increasing awareness pertaining to EDC solutions is predicted to fuel the demand in near future. Moreover, government organizations such as Agency for Healthcare Research and Quality and The Office of National Coordinator for Health Information Technology are promoting the adoption of electronic systems for data management. The aforementioned factors have resulted in the rising adoption of electronic data collection by pharmaceutical companies.

Moreover, increasing adoption of EDC systems by major pharmaceuticals to propagate clinical trials is predicted to provide this market with lucrative growth. For instance, in May 2016, Simbec-Orion Group selected Oracle's product, the Siebel Clinical Trial Management System, to strengthen its development processes and to expand its international operations & business. The system will provide efficient data capture and speed up the trial timelines. The strategies like this are anticipated to boost demand in coming years.

                           View summary of this report, Click Here 

Further Key Findings From the Study Suggest: 

• The software segment is predicted to witness lucrative growth owing to growing adoption by large pharmaceutical companies
• The cloud-based segment is anticipated to experience the fastest growth as it allows easy data access over remote locations and provides larger storage space
• Phase I clinical trials segment is expected to exhibit fastest CAGR over the forecast period as consequence of the rising R&D expenditure on the development of novel drugs by pharmaceutical companies
• CROs held the largest revenue share of EDC systems owing to rising demand from major players in the medical device sector
• Asia Pacific market for EDC systems is anticipated to witness highest growth rate owing to the presence of large number of outsourcing firms in this region offering cost-efficient eClinical solutions
• The market is facing intense competition as there are many organizations that offer technologically efficient solutions for clinical data management
• Companies are adopting strategies such as merger & acquisition, new product development, and distribution channel enhancement to gain competitive advantage

Click Here For Access Full Report : https://goo.gl/AvFbFW